Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the launch of more-expensive emerging agents with regulatory approval for neuropathic pain will drive growth in the key neuropathic pain markets. Market growth will reflect a shift in treatment practices as physicians who historically relied on relatively inexpensive, off-label generic therapies turn to more-expensive, approved drugs.

"Drug manufacturers are hoping to grab share in this growing market," said Elana Feldman, analyst at Decision Resources. "After witnessing the success of Pfizer's Neurontin, one of the only drugs currently approved for neuropathic pain, companies are realizing that they can boost sales for products traditionally indicated for other diseases by pursuing supplementary approval for neuropathic pain."

The new Pharmacor study entitled Neuropathic Pain: Painful Diabetic Neuropathy, Postherpetic Neuralgia, and HIV-Related Neuropathic Pain also finds that Pfizer's antiepileptic drug pregabalin and Eli Lilly's antidepressant duloxetine will improve awareness among physicians, particularly primary care practitioners, of neuropathic pain diagnoses and treatments. This awareness will lead to a steady increase in the number of diagnosed and drug-treated neuropathic pain patients.

About Neuropathic Pain

Neuropathic Pain is an in-depth analysis of prescription drug therapies used to treat painful diabetic neuropathy, postherpetic neuralgia, and HIV- related neuropathic pain. The study uncovers a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Neuropathic Pain is part of the Pain Portfolio from Decision Resources, a series of studies and reports that provide a comprehensive view of individual pain markets.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563
emarshall@dresources.com

Perception That HMOs and PPOs Are Rivals Not True

View Now